A Madison-based medical technology startup says a personalized heart failure treatment it is developing is nearing the FDA application process.

While other areas of disease including cancer screenings have caught up to the advancements in personalized treatment, targeted treatment for heart disease still has a long way to go, said Ayla Annac, president and CEO of InvivoSciences.

Annac and her company hope to fill that need.

Click here to read the full article.